Patrick Schnegelsberg

SynCardia Systems LLC engages in the manufacture of temporary total artificial heart. Its total artificial heart provides immediate, safe blood flow of up to 9.5 L/min through each ventricle. The company was founded by Marvin J. Slepian, Jack G. Copeland, and Richard G. Smith in 2001 and is headquartered in Tucson, AZ.

Acorai AB is a Swedish medical device company founded in 2019. The company is based in Stockholm, Sweden. The company is developing a scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.

Syntach AB is a Swedish company based in Lund that specializes in developing a revolutionary, minimally invasive long-term cardiac support device and mitral valve repair technology for people suffering from severe heart failure. Syntach has close links and extensive cooperation with various institutions at the University of Lund. The company is also developing a minimally-invasive device to correct mitral valve regurgitation, which can be used in combination with the cardiac support device or on a standalone basis. The company was founded in 2012 with the aim of creating an entirely new class of cardiac support devices to improve the care of the rapidly-growing number of people with heart failure. The company was founded by Tor Peters and Jan Otto Solem, who have been the CEOs since incorporation.

Scandinavian Real Heart AB engages in the development of mechanical cardiac pumps. It offers an artificial heart that recreates the flow, pressure, and control of a pumping heart and can be used for patients awaiting heart transplants. The company was founded by Azad Najar, Gunnar Nihlén, and Said Zahrai in 1999 and is headquartered in Västerås, Sweden.

Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel.